AU Engine

Source: Resmed Inc

• Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis 
• GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8%
• GAAP income from operations increased 17%; non-GAAP income from operations up 18%
• GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per share of $2.86
• Operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends

Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) — Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2026.

“Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined execution of our strategy,” said Resmed’s Chairman and CEO, Mick Farrell.

“Year-over-year, we delivered 11% reported revenue growth, 290 basis points of non-GAAP gross margin expansion, and 21% increase in earnings per share. These results highlight the momentum behind our strategy, and the continued progress we are making in shaping the future of sleep health, breathing health, and healthcare in the home.

As we advance through the remainder of our fiscal year 2026, we remain focused on expanding access to care globally, scaling our digital health capabilities, and delivering further strong, profitable growth.”

Financial Results and Operating Metrics

Unaudited; $ in millions, except for per share amounts

	Three Months Ended
	March 31, 2026				March 31, 2025				% Change			Constant Currency (A)
Revenue	$	1,431.4			$	1,291.7			11	%		8	%
Gross margin		62.2	%			59.3	%		5
Non-GAAP gross margin (B)		62.8	%			59.9	%		5
Selling, general, and administrative expenses		285.7				245.3			16			11
Non-GAAP selling, general, and administrative expenses(B)		279.8				245.3			14			9
Research and development expenses		94.3				83.9			12			8
Income from operations		499.8				426.3			17
Non-GAAP income from operations (B)		524.8				444.6			18
Net income		398.7				365.0			9
Non-GAAP net income (B)		417.2				348.5			20
Diluted earnings per share	$	2.74			$	2.48			10
Non-GAAP diluted earnings per share (B)	$	2.86			$	2.37			21

	Nine Months Ended
	March 31, 2026				March 31, 2025				% Change			Constant Currency (A)
Revenue	$	4,189.8			$	3,798.3			10	%		8	%
Gross margin		61.8	%			58.8	%		5
Non-GAAP gross margin (B)		62.4	%			59.4	%		5
Selling, general, and administrative expenses		823.2				725.9			13			10
Non-GAAP selling, general, and administrative expenses(B)		817.4				725.9			13			9
Research and development expenses		272.6				244.8			11			9
Income from operations		1,438.0				1,230.8			17
Non-GAAP income from operations (B)		1,524.1				1,286.9			18
Net income		1,139.9				1,021.0			12
Non-GAAP net income (B)		1,203.5				1,032.2			17
Diluted earnings per share	$	7.79			$	6.93			12
Non-GAAP diluted earnings per share (B)	$	8.22			$	7.00			17

(A)	In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
(B)	See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Discussion of Third Quarter Results
All comparisons are to the prior year period unless otherwise noted

• Revenue grew by 8 percent on a constant currency basis, driven by increased demand for our portfolio of sleep devices, masks and accessories.
  • Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 9 percent.
  • Revenue in Europe, Asia, and other markets, excluding Residential Care Software, grew by 7 percent on a constant currency basis.
  • Residential Care Software revenue increased by 4 percent on a constant currency basis.
• Gross margin increased by 290 basis points primarily driven by component cost improvements and manufacturing and logistics efficiencies, as well as a small positive impact from product mix and foreign currency movements. Non-GAAP gross margin increased by 290 basis points due to the same factors.
• Selling, general, and administrative expenses increased by 11 percent on a constant currency basis. The increase in SG&A expenses was mainly due to additional expenses associated with our VirtuOx acquisition, employee costs as well as marketing and technology investments. Additionally, we recorded acquisition and portfolio review related expenses of $5.9 million reflecting costs associated with the evaluation of strategic transactions, including legal and professional fees for diligence and related consultations. SG&A expenses, excluding acquisition and portfolio review related expenses, were 19.5 percent of revenue in the quarter, compared with 19.0 percent in the same period of the prior year.
• Income from operations increased by 17 percent and non-GAAP income from operations increased by 18 percent.
• Net income for the quarter was $399 million and diluted earnings per share was $2.74. Non-GAAP net income increased by 20 percent to $417 million, and non-GAAP diluted earnings per share increased by 21 percent to $2.86, predominantly attributable to strong sales growth and gross margin improvement.
• Operating cash flow for the quarter was $554 million, compared to net income in the current quarter of $399 million and non-GAAP net income of $417 million.
• During the quarter, we paid $87 million in dividends to shareholders and repurchased 673,000 shares for consideration of $175 million as part of our ongoing capital management.

Other Business and Operational Highlights

• Unveiled findings from sixth annual Global Sleep Survey, drawing insights from 30,000 people across 13 countries; as sleep awareness grows, so does the opportunity to turn intent into action.
• Announced expansion of U.S. operations with new distribution center in Greenwood, Indiana, scheduled to begin operations in 2027 and expand Resmed’s U.S. presence while strengthening the company’s distribution capacity to better serve patients and providers across North America.
• Launched the AirTouch F30i Comfort full face mask in the U.S. following its introduction in Australia and Canada, and building on the launch of the AirTouch F30i Clear in the U.S.

Dividend program
The Resmed board of directors today declared a quarterly cash dividend of $0.60 per share. The dividend will have a record date of May 14, 2026, payable on June 18, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 13, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from May 13, 2026, through May 14, 2026, inclusive. 

Webcast details
Resmed will discuss its third quarter fiscal year 2026 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q3 2026 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13759381. The telephone replay will be available until May 14, 2026.

About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

Safe harbor statement
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements.

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts)

	Three Months Ended								Nine Months Ended
	March 31, 2026				March 31, 2025				March 31, 2026				March 31, 2025
Net revenue	$	1,431,406			$	1,291,736			$	4,189,796			$	3,798,334
Cost of sales		532,577				517,883				1,575,796				1,540,684
Amortization of acquired intangibles (1)		7,850				7,444				23,480				22,748
Total cost of sales	$	540,427			$	525,327			$	1,599,276			$	1,563,432
Gross profit	$	890,979			$	766,409			$	2,590,520			$	2,234,902
Selling, general, and administrative		279,797				245,302				817,387				725,894
Acquisition and portfolio review related expenses (1)		5,858				—				5,858				—
Total selling, general, and administrative		285,655				245,302				823,245				725,894
Research and development		94,267				83,944				272,560				244,840
Amortization of acquired intangibles (1)		11,247				10,895				34,967				33,345
Restructuring expenses (1)		—				—				21,745				—
Total operating expenses	$	391,169			$	340,141			$	1,152,517			$	1,004,079
Income from operations	$	499,810			$	426,268			$	1,438,003			$	1,230,823
Other income (expenses), net:
Interest (expense) income, net	$	12,287			$	793			$	29,029			$	(1,643	)
Gain (loss) attributable to equity method investments		1,718				335				4,722				2,375
Gain (loss) on equity investments		(10,130	)			(5,647	)			(16,014	)			(7,765	)
Other, net		(1,373	)			(4,056	)			(10,488	)			(4,277	)
Total other income (expenses), net		2,502				(8,575	)			7,249				(11,310	)
Income before income taxes	$	502,312			$	417,693			$	1,445,252			$	1,219,513
Income taxes		103,580				52,652				305,391				198,495
Net income	$	398,732			$	365,041			$	1,139,861			$	1,021,018
Basic earnings per share	$	2.74			$	2.49			$	7.82			$	6.96
Diluted earnings per share	$	2.74			$	2.48			$	7.79			$	6.93
Non-GAAP diluted earnings per share (1)	$	2.86			$	2.37			$	8.22			$	7.00
Basic shares outstanding		145,340				146,719				145,794				146,797
Diluted shares outstanding		145,723				147,220				146,369				147,432

(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands)

	March 31, 2026				June 30, 2025
Assets
Current assets:
Cash and cash equivalents	$	1,660,513			$	1,209,450
Accounts receivable, net		998,837				939,492
Inventories		911,876				927,711
Prepayments and other current assets		492,836				428,952
Total current assets	$	4,064,062			$	3,505,605
Non-current assets:
Property, plant, and equipment, net	$	566,972			$	550,790
Operating lease right-of-use assets		161,602				167,497
Goodwill and other intangibles, net		3,468,321				3,511,541
Deferred income taxes and other non-current assets		523,328				438,958
Total non-current assets	$	4,720,223			$	4,668,786
Total assets	$	8,784,285			$	8,174,391
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	273,301			$	278,157
Accrued expenses		446,149				402,253
Operating lease liabilities, current		29,233				30,506
Deferred revenue		179,277				166,030
Income taxes payable		163,322				132,274
Short-term debt		259,928				9,900
Total current liabilities	$	1,351,210			$	1,019,120
Non-current liabilities:
Deferred revenue	$	163,148			$	156,803
Deferred income taxes		77,929				77,682
Operating lease liabilities, non-current		149,840				153,015
Other long-term liabilities		146,079				141,520
Long-term debt		404,168				658,392
Total non-current liabilities	$	941,164			$	1,187,412
Total liabilities	$	2,292,374			$	2,206,532
Stockholders’ equity
Common stock	$	763			$	761
Additional paid-in capital		2,134,231				2,033,599
Retained earnings		6,958,779				6,081,490
Treasury stock		(2,576,957	)			(2,073,292	)
Accumulated other comprehensive income		(24,905	)			(74,699	)
Total stockholders’ equity	$	6,491,911			$	5,967,859
Total liabilities and stockholders’ equity	$	8,784,285			$	8,174,391

Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands)

	Three Months Ended								Nine Months Ended
	March 31, 2026				March 31, 2025				March 31, 2026				March 31, 2025
Cash flows from operating activities:
Net income	$	398,732			$	365,041			$	1,139,861			$	1,021,018
Adjustment to reconcile net income to cash provided by operating activities:
Depreciation and amortization		58,981				43,675				156,564				134,845
Amortization of right-of-use assets		10,051				8,235				32,467				26,678
Stock-based compensation costs		26,792				24,120				76,890				66,910
(Gain) loss attributable to equity method investments, net of dividends received		(1,718	)			(335	)			(4,722	)			(2,375	)
(Gain) loss on equity investments		10,130				5,647				16,014				7,765
Changes in operating assets and liabilities:
Accounts receivable, net		(16,857	)			(40,033	)			(59,569	)			(71,469	)
Inventories, net		12,480				29,864				23,946				(48,032	)
Prepaid expenses, net deferred income taxes and other current assets		(48,335	)			79,357				(152,410	)			35,612
Accounts payable, accrued expenses, income taxes payable and other		103,876				63,091				122,157				41,870
Net cash provided by (used in) operating activities	$	554,132			$	578,662			$	1,351,198			$	1,212,822
Cash flows from investing activities:
Purchases of property, plant, and equipment		(33,654	)			(20,796	)			(105,158	)			(59,280	)
Patent registration and acquisition costs		(5,935	)			(2,992	)			(13,286	)			(7,584	)
Purchases of intangible assets		—				—				(1,479	)			—
Business acquisitions, net of cash acquired		(24,883	)			—				(25,405	)			(670	)
Purchases of investments		(20,132	)			(2,053	)			(26,536	)			(4,403	)
Proceeds from exits of investments		2,502				—				2,752				4,378
Proceeds (payments) on maturity of foreign currency contracts		24,074				(5,945	)			7,564				1,227
Net cash provided by (used in) investing activities	$	(58,028	)		$	(31,786	)		$	(161,548	)		$	(66,332	)
Cash flows from financing activities:
Proceeds from issuance of common stock, net		7,427				9,022				45,189				44,283
Purchases of treasury stock		(175,013	)			(75,026	)			(500,037	)			(200,017	)
Taxes paid related to net share settlement of equity awards		(418	)			(364	)			(21,445	)			(17,487	)
Payments of business combination contingent consideration		—				—				—				(855	)
Repayment of borrowings		—				—				(5,000	)			(35,000	)
Dividends paid		(87,238	)			(77,704	)			(262,572	)			(233,290	)
Net cash provided by (used in) financing activities	$	(255,242	)		$	(144,072	)		$	(743,865	)		$	(442,366	)
Effect of exchange rate changes on cash	$	2,582			$	7,963			$	5,278			$	(9,774	)
Net increase (decrease) in cash and cash equivalents		243,444				410,767				451,063				694,350
Cash and cash equivalents at beginning of period		1,417,069				521,944				1,209,450				238,361
Cash and cash equivalents at end of period	$	1,660,513			$	932,711			$	1,660,513			$	932,711

Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and are reconciled below:

	Three Months Ended								Nine Months Ended
	March 31, 2026				March 31, 2025				March 31, 2026				March 31, 2025
Revenue	$	1,431,406			$	1,291,736			$	4,189,796			$	3,798,334
GAAP cost of sales	$	540,427			$	525,327			$	1,599,276			$	1,563,432
Less: Amortization of acquired intangibles (A)		(7,850	)			(7,444	)			(23,480	)			(22,748	)
Non-GAAP cost of sales	$	532,577			$	517,883			$	1,575,796			$	1,540,684
GAAP gross profit	$	890,979			$	766,409			$	2,590,520			$	2,234,902
GAAP gross margin		62.2	%			59.3	%			61.8	%			58.8	%
Non-GAAP gross profit	$	898,829			$	773,853			$	2,614,000			$	2,257,650
Non-GAAP gross margin		62.8	%			59.9	%			62.4	%			59.4	%

The measures “non-GAAP selling, general, and administrative expenses” and “non-GAAP selling, general, and administrative expenses as a percentage of revenues” exclude acquisition and portfolio review related expenses and are reconciled below:

	Three Months Ended								Nine Months Ended
	March 31, 2026				March 31, 2025				March 31, 2026				March 31, 2025
Revenue	$	1,431,406			$	1,291,736			$	4,189,796			$	3,798,334
GAAP selling, general, and administrative		285,655				245,302				823,245				725,894
Less: Acquisition and portfolio review related expenses (A)		(5,858	)			—				(5,858	)			—
Non-GAAP selling, general, and administrative		279,797				245,302				817,387				725,894
As a percentage of revenue:
GAAP selling, general, and administrative expenses		20.0	%			19.0	%			19.6	%			19.1	%
Non-GAAP selling, general, and administrative expenses		19.5	%			19.0	%			19.5	%			19.1	%

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

	Three Months Ended						Nine Months Ended
	March 31, 2026			March 31, 2025			March 31, 2026			March 31, 2025
GAAP income from operations	$	499,810		$	426,268		$	1,438,003		$	1,230,823
Amortization of acquired intangibles—cost of sales (A)		7,850			7,444			23,480			22,748
Amortization of acquired intangibles—operating expenses (A)		11,247			10,895			34,967			33,345
Restructuring (A)		—			—			21,745			—
Acquisition and portfolio review related expenses (A)		5,858			—			5,858			—
Non-GAAP income from operations	$	524,765		$	444,607		$	1,524,053		$	1,286,916

Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

	Three Months Ended								Nine Months Ended
	March 31, 2026				March 31, 2025				March 31, 2026				March 31, 2025
GAAP net income	$	398,732			$	365,041			$	1,139,861			$	1,021,018
Amortization of acquired intangibles—cost of sales (A)		7,850				7,444				23,480				22,748
Amortization of acquired intangibles—operating expenses (A)		11,247				10,895				34,967				33,345
Restructuring expenses (A)		—				—				21,745				—
Acquisition and portfolio review related expenses (A)		5,858				—				5,858				—
Income tax effect of interest and penalties on income tax refunds (A)		—				(29,976	)			—				(29,976	)
Income tax effect on non-GAAP adjustments (A)		(6,519	)			(4,871	)			(22,394	)			(14,904	)
Non-GAAP net income (A)	$	417,168			$	348,533			$	1,203,517			$	1,032,231
GAAP diluted shares outstanding		145,723				147,220				146,369				147,432
GAAP diluted earnings per share	$	2.74			$	2.48			$	7.79			$	6.93
Non-GAAP diluted earnings per share (A)	$	2.86			$	2.37			$	8.22			$	7.00

(A)	Resmed adjusts for the impact of the amortization of acquired intangibles, restructuring expenses, and acquisition and portfolio review related expenses from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.
	Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

Revenue by Product and Region
(Unaudited; $ in millions, except for per share amounts)

	Three Months Ended
	March 31, 2026		(A)	March 31, 2025		(A)	% Change			Constant Currency (B)
U.S., Canada, and Latin America
Devices	$	447.5		$	422.7		6	%
Masks and other		371.2			326.7		14
Total U.S., Canada and Latin America	$	818.7		$	749.3		9
Combined Europe, Asia, and other markets
Devices	$	288.2		$	253.5		14	%		6	%
Masks and other		153.6			127.7		20			10
Total Combined Europe, Asia and other markets	$	441.8		$	381.3		16			7
Global revenue
Total Devices	$	735.7		$	676.2		9	%		6	%
Total Masks and other		524.8			454.4		15			12
Total Sleep and Breathing Health	$	1,260.5		$	1,130.6		11			8
Residential Care Software		170.9			161.2		6			4
Total	$	1,431.4		$	1,291.7		11			8

	Nine Months Ended
	March 31, 2026		(A)	March 31, 2025		(A)	% Change			Constant Currency (B)
U.S., Canada, and Latin America
Devices	$	1,309.0		$	1,221.6		7	%
Masks and other		1,119.5			983.9		14
Total U.S., Canada and Latin America	$	2,428.5		$	2,205.6		10
Combined Europe, Asia, and other markets
Devices	$	833.3		$	749.6		11	%		6	%
Masks and other		424.2			368.7		15			7
Total Combined Europe, Asia and other markets	$	1,257.4		$	1,118.3		12			6
Global revenue
Total Devices	$	2,142.3		$	1,971.3		9	%		7	%
Total Masks and other		1,543.6			1,352.6		14			12
Total Sleep and Breathing Health	$	3,685.9		$	3,323.9		11			9
Residential Care Software		503.9			474.4		6			4
Total	$	4,189.8		$	3,798.3		10			8

(A)	Totals and subtotals may not add due to rounding.
(B)	In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

Source: Resmed, Inc.

Released April 30, 2026

Source: Resmed Inc

• Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis 
• GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8%
• GAAP income from operations increased 17%; non-GAAP income from operations up 18%
• GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per share of $2.86
• Operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends

Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) — Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2026.

“Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined execution of our strategy,” said Resmed’s Chairman and CEO, Mick Farrell.

“Year-over-year, we delivered 11% reported revenue growth, 290 basis points of non-GAAP gross margin expansion, and 21% increase in earnings per share. These results highlight the momentum behind our strategy, and the continued progress we are making in shaping the future of sleep health, breathing health, and healthcare in the home.

As we advance through the remainder of our fiscal year 2026, we remain focused on expanding access to care globally, scaling our digital health capabilities, and delivering further strong, profitable growth.”

Financial Results and Operating Metrics

Unaudited; $ in millions, except for per share amounts

	Three Months Ended
	March 31, 2026				March 31, 2025				% Change			Constant Currency (A)
Revenue	$	1,431.4			$	1,291.7			11	%		8	%
Gross margin		62.2	%			59.3	%		5
Non-GAAP gross margin (B)		62.8	%			59.9	%		5
Selling, general, and administrative expenses		285.7				245.3			16			11
Non-GAAP selling, general, and administrative expenses(B)		279.8				245.3			14			9
Research and development expenses		94.3				83.9			12			8
Income from operations		499.8				426.3			17
Non-GAAP income from operations (B)		524.8				444.6			18
Net income		398.7				365.0			9
Non-GAAP net income (B)		417.2				348.5			20
Diluted earnings per share	$	2.74			$	2.48			10
Non-GAAP diluted earnings per share (B)	$	2.86			$	2.37			21

	Nine Months Ended
	March 31, 2026				March 31, 2025				% Change			Constant Currency (A)
Revenue	$	4,189.8			$	3,798.3			10	%		8	%
Gross margin		61.8	%			58.8	%		5
Non-GAAP gross margin (B)		62.4	%			59.4	%		5
Selling, general, and administrative expenses		823.2				725.9			13			10
Non-GAAP selling, general, and administrative expenses(B)		817.4				725.9			13			9
Research and development expenses		272.6				244.8			11			9
Income from operations		1,438.0				1,230.8			17
Non-GAAP income from operations (B)		1,524.1				1,286.9			18
Net income		1,139.9				1,021.0			12
Non-GAAP net income (B)		1,203.5				1,032.2			17
Diluted earnings per share	$	7.79			$	6.93			12
Non-GAAP diluted earnings per share (B)	$	8.22			$	7.00			17

(A)	In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency” basis, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.
(B)	See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Discussion of Third Quarter Results
All comparisons are to the prior year period unless otherwise noted

• Revenue grew by 8 percent on a constant currency basis, driven by increased demand for our portfolio of sleep devices, masks and accessories.
  • Revenue in the U.S., Canada, and Latin America, excluding Residential Care Software, grew by 9 percent.
  • Revenue in Europe, Asia, and other markets, excluding Residential Care Software, grew by 7 percent on a constant currency basis.
  • Residential Care Software revenue increased by 4 percent on a constant currency basis.
• Gross margin increased by 290 basis points primarily driven by component cost improvements and manufacturing and logistics efficiencies, as well as a small positive impact from product mix and foreign currency movements. Non-GAAP gross margin increased by 290 basis points due to the same factors.
• Selling, general, and administrative expenses increased by 11 percent on a constant currency basis. The increase in SG&A expenses was mainly due to additional expenses associated with our VirtuOx acquisition, employee costs as well as marketing and technology investments. Additionally, we recorded acquisition and portfolio review related expenses of $5.9 million reflecting costs associated with the evaluation of strategic transactions, including legal and professional fees for diligence and related consultations. SG&A expenses, excluding acquisition and portfolio review related expenses, were 19.5 percent of revenue in the quarter, compared with 19.0 percent in the same period of the prior year.
• Income from operations increased by 17 percent and non-GAAP income from operations increased by 18 percent.
• Net income for the quarter was $399 million and diluted earnings per share was $2.74. Non-GAAP net income increased by 20 percent to $417 million, and non-GAAP diluted earnings per share increased by 21 percent to $2.86, predominantly attributable to strong sales growth and gross margin improvement.
• Operating cash flow for the quarter was $554 million, compared to net income in the current quarter of $399 million and non-GAAP net income of $417 million.
• During the quarter, we paid $87 million in dividends to shareholders and repurchased 673,000 shares for consideration of $175 million as part of our ongoing capital management.

Other Business and Operational Highlights

• Unveiled findings from sixth annual Global Sleep Survey, drawing insights from 30,000 people across 13 countries; as sleep awareness grows, so does the opportunity to turn intent into action.
• Announced expansion of U.S. operations with new distribution center in Greenwood, Indiana, scheduled to begin operations in 2027 and expand Resmed’s U.S. presence while strengthening the company’s distribution capacity to better serve patients and providers across North America.
• Launched the AirTouch F30i Comfort full face mask in the U.S. following its introduction in Australia and Canada, and building on the launch of the AirTouch F30i Clear in the U.S.

Dividend program
The Resmed board of directors today declared a quarterly cash dividend of $0.60 per share. The dividend will have a record date of May 14, 2026, payable on June 18, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. The ex-dividend date will be May 13, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from May 13, 2026, through May 14, 2026, inclusive. 

Webcast details
Resmed will discuss its third quarter fiscal year 2026 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q3 2026 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing +1 877-660-6853 (U.S.) or +1 201-612-7415 (outside U.S.) and entering the passcode 13759381. The telephone replay will be available until May 14, 2026.

About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

Safe harbor statement
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities & Exchange Commission. Resmed does not undertake to update its forward-looking statements.

RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations
(Unaudited; $ in thousands, except for per share amounts)

	Three Months Ended								Nine Months Ended
	March 31, 2026				March 31, 2025				March 31, 2026				March 31, 2025
Net revenue	$	1,431,406			$	1,291,736			$	4,189,796			$	3,798,334
Cost of sales		532,577				517,883				1,575,796				1,540,684
Amortization of acquired intangibles (1)		7,850				7,444				23,480				22,748
Total cost of sales	$	540,427			$	525,327			$	1,599,276			$	1,563,432
Gross profit	$	890,979			$	766,409			$	2,590,520			$	2,234,902
Selling, general, and administrative		279,797				245,302				817,387				725,894
Acquisition and portfolio review related expenses (1)		5,858				—				5,858				—
Total selling, general, and administrative		285,655				245,302				823,245				725,894
Research and development		94,267				83,944				272,560				244,840
Amortization of acquired intangibles (1)		11,247				10,895				34,967				33,345
Restructuring expenses (1)		—				—				21,745				—
Total operating expenses	$	391,169			$	340,141			$	1,152,517			$	1,004,079
Income from operations	$	499,810			$	426,268			$	1,438,003			$	1,230,823
Other income (expenses), net:
Interest (expense) income, net	$	12,287			$	793			$	29,029			$	(1,643	)
Gain (loss) attributable to equity method investments		1,718				335				4,722				2,375
Gain (loss) on equity investments		(10,130	)			(5,647	)			(16,014	)			(7,765	)
Other, net		(1,373	)			(4,056	)			(10,488	)			(4,277	)
Total other income (expenses), net		2,502				(8,575	)			7,249				(11,310	)
Income before income taxes	$	502,312			$	417,693			$	1,445,252			$	1,219,513
Income taxes		103,580				52,652				305,391				198,495
Net income	$	398,732			$	365,041			$	1,139,861			$	1,021,018
Basic earnings per share	$	2.74			$	2.49			$	7.82			$	6.96
Diluted earnings per share	$	2.74			$	2.48			$	7.79			$	6.93
Non-GAAP diluted earnings per share (1)	$	2.86			$	2.37			$	8.22			$	7.00
Basic shares outstanding		145,340				146,719				145,794				146,797
Diluted shares outstanding		145,723				147,220				146,369				147,432

(1) See the reconciliation of non-GAAP financial measures in the table at the end of the press release.

Condensed Consolidated Balance Sheets
(Unaudited; $ in thousands)

	March 31, 2026				June 30, 2025
Assets
Current assets:
Cash and cash equivalents	$	1,660,513			$	1,209,450
Accounts receivable, net		998,837				939,492
Inventories		911,876				927,711
Prepayments and other current assets		492,836				428,952
Total current assets	$	4,064,062			$	3,505,605
Non-current assets:
Property, plant, and equipment, net	$	566,972			$	550,790
Operating lease right-of-use assets		161,602				167,497
Goodwill and other intangibles, net		3,468,321				3,511,541
Deferred income taxes and other non-current assets		523,328				438,958
Total non-current assets	$	4,720,223			$	4,668,786
Total assets	$	8,784,285			$	8,174,391
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	273,301			$	278,157
Accrued expenses		446,149				402,253
Operating lease liabilities, current		29,233				30,506
Deferred revenue		179,277				166,030
Income taxes payable		163,322				132,274
Short-term debt		259,928				9,900
Total current liabilities	$	1,351,210			$	1,019,120
Non-current liabilities:
Deferred revenue	$	163,148			$	156,803
Deferred income taxes		77,929				77,682
Operating lease liabilities, non-current		149,840				153,015
Other long-term liabilities		146,079				141,520
Long-term debt		404,168				658,392
Total non-current liabilities	$	941,164			$	1,187,412
Total liabilities	$	2,292,374			$	2,206,532
Stockholders’ equity
Common stock	$	763			$	761
Additional paid-in capital		2,134,231				2,033,599
Retained earnings		6,958,779				6,081,490
Treasury stock		(2,576,957	)			(2,073,292	)
Accumulated other comprehensive income		(24,905	)			(74,699	)
Total stockholders’ equity	$	6,491,911			$	5,967,859
Total liabilities and stockholders’ equity	$	8,784,285			$	8,174,391

Condensed Consolidated Statements of Cash Flows
(Unaudited; $ in thousands)

	Three Months Ended								Nine Months Ended
	March 31, 2026				March 31, 2025				March 31, 2026				March 31, 2025
Cash flows from operating activities:
Net income	$	398,732			$	365,041			$	1,139,861			$	1,021,018
Adjustment to reconcile net income to cash provided by operating activities:
Depreciation and amortization		58,981				43,675				156,564				134,845
Amortization of right-of-use assets		10,051				8,235				32,467				26,678
Stock-based compensation costs		26,792				24,120				76,890				66,910
(Gain) loss attributable to equity method investments, net of dividends received		(1,718	)			(335	)			(4,722	)			(2,375	)
(Gain) loss on equity investments		10,130				5,647				16,014				7,765
Changes in operating assets and liabilities:
Accounts receivable, net		(16,857	)			(40,033	)			(59,569	)			(71,469	)
Inventories, net		12,480				29,864				23,946				(48,032	)
Prepaid expenses, net deferred income taxes and other current assets		(48,335	)			79,357				(152,410	)			35,612
Accounts payable, accrued expenses, income taxes payable and other		103,876				63,091				122,157				41,870
Net cash provided by (used in) operating activities	$	554,132			$	578,662			$	1,351,198			$	1,212,822
Cash flows from investing activities:
Purchases of property, plant, and equipment		(33,654	)			(20,796	)			(105,158	)			(59,280	)
Patent registration and acquisition costs		(5,935	)			(2,992	)			(13,286	)			(7,584	)
Purchases of intangible assets		—				—				(1,479	)			—
Business acquisitions, net of cash acquired		(24,883	)			—				(25,405	)			(670	)
Purchases of investments		(20,132	)			(2,053	)			(26,536	)			(4,403	)
Proceeds from exits of investments		2,502				—				2,752				4,378
Proceeds (payments) on maturity of foreign currency contracts		24,074				(5,945	)			7,564				1,227
Net cash provided by (used in) investing activities	$	(58,028	)		$	(31,786	)		$	(161,548	)		$	(66,332	)
Cash flows from financing activities:
Proceeds from issuance of common stock, net		7,427				9,022				45,189				44,283
Purchases of treasury stock		(175,013	)			(75,026	)			(500,037	)			(200,017	)
Taxes paid related to net share settlement of equity awards		(418	)			(364	)			(21,445	)			(17,487	)
Payments of business combination contingent consideration		—				—				—				(855	)
Repayment of borrowings		—				—				(5,000	)			(35,000	)
Dividends paid		(87,238	)			(77,704	)			(262,572	)			(233,290	)
Net cash provided by (used in) financing activities	$	(255,242	)		$	(144,072	)		$	(743,865	)		$	(442,366	)
Effect of exchange rate changes on cash	$	2,582			$	7,963			$	5,278			$	(9,774	)
Net increase (decrease) in cash and cash equivalents		243,444				410,767				451,063				694,350
Cash and cash equivalents at beginning of period		1,417,069				521,944				1,209,450				238,361
Cash and cash equivalents at end of period	$	1,660,513			$	932,711			$	1,660,513			$	932,711

Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and are reconciled below:

	Three Months Ended								Nine Months Ended
	March 31, 2026				March 31, 2025				March 31, 2026				March 31, 2025
Revenue	$	1,431,406			$	1,291,736			$	4,189,796			$	3,798,334
GAAP cost of sales	$	540,427			$	525,327			$	1,599,276			$	1,563,432
Less: Amortization of acquired intangibles (A)		(7,850	)			(7,444	)			(23,480	)			(22,748	)
Non-GAAP cost of sales	$	532,577			$	517,883			$	1,575,796			$	1,540,684
GAAP gross profit	$	890,979			$	766,409			$	2,590,520			$	2,234,902
GAAP gross margin		62.2	%			59.3	%			61.8	%			58.8	%
Non-GAAP gross profit	$	898,829			$	773,853			$	2,614,000			$	2,257,650
Non-GAAP gross margin		62.8	%			59.9	%			62.4	%			59.4	%

The measures “non-GAAP selling, general, and administrative expenses” and “non-GAAP selling, general, and administrative expenses as a percentage of revenues” exclude acquisition and portfolio review related expenses and are reconciled below:

	Three Months Ended								Nine Months Ended
	March 31, 2026				March 31, 2025				March 31, 2026				March 31, 2025
Revenue	$	1,431,406			$	1,291,736			$	4,189,796			$	3,798,334
GAAP selling, general, and administrative		285,655				245,302				823,245				725,894
Less: Acquisition and portfolio review related expenses (A)		(5,858	)			—				(5,858	)			—
Non-GAAP selling, general, and administrative		279,797				245,302				817,387				725,894
As a percentage of revenue:
GAAP selling, general, and administrative expenses		20.0	%			19.0	%			19.6	%			19.1	%
Non-GAAP selling, general, and administrative expenses		19.5	%			19.0	%			19.5	%			19.1	%

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

	Three Months Ended						Nine Months Ended
	March 31, 2026			March 31, 2025			March 31, 2026			March 31, 2025
GAAP income from operations	$	499,810		$	426,268		$	1,438,003		$	1,230,823
Amortization of acquired intangibles—cost of sales (A)		7,850			7,444			23,480			22,748
Amortization of acquired intangibles—operating expenses (A)		11,247			10,895			34,967			33,345
Restructuring (A)		—			—			21,745			—
Acquisition and portfolio review related expenses (A)		5,858			—			5,858			—
Non-GAAP income from operations	$	524,765		$	444,607		$	1,524,053		$	1,286,916

Reconciliation of Non-GAAP Financial Measures
(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

	Three Months Ended								Nine Months Ended
	March 31, 2026				March 31, 2025				March 31, 2026				March 31, 2025
GAAP net income	$	398,732			$	365,041			$	1,139,861			$	1,021,018
Amortization of acquired intangibles—cost of sales (A)		7,850				7,444				23,480				22,748
Amortization of acquired intangibles—operating expenses (A)		11,247				10,895				34,967				33,345
Restructuring expenses (A)		—				—				21,745				—
Acquisition and portfolio review related expenses (A)		5,858				—				5,858				—
Income tax effect of interest and penalties on income tax refunds (A)		—				(29,976	)			—				(29,976	)
Income tax effect on non-GAAP adjustments (A)		(6,519	)			(4,871	)			(22,394	)			(14,904	)
Non-GAAP net income (A)	$	417,168			$	348,533			$	1,203,517			$	1,032,231
GAAP diluted shares outstanding		145,723				147,220				146,369				147,432
GAAP diluted earnings per share	$	2.74			$	2.48			$	7.79			$	6.93
Non-GAAP diluted earnings per share (A)	$	2.86			$	2.37			$	8.22			$	7.00

(A)	Resmed adjusts for the impact of the amortization of acquired intangibles, restructuring expenses, and acquisition and portfolio review related expenses from their evaluation of ongoing operations, and believes that investors benefit from adjusting these items to facilitate a more meaningful evaluation of current operating performance.
	Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP.

Revenue by Product and Region
(Unaudited; $ in millions, except for per share amounts)

	Three Months Ended
	March 31, 2026		(A)	March 31, 2025		(A)	% Change			Constant Currency (B)
U.S., Canada, and Latin America
Devices	$	447.5		$	422.7		6	%
Masks and other		371.2			326.7		14
Total U.S., Canada and Latin America	$	818.7		$	749.3		9
Combined Europe, Asia, and other markets
Devices	$	288.2		$	253.5		14	%		6	%
Masks and other		153.6			127.7		20			10
Total Combined Europe, Asia and other markets	$	441.8		$	381.3		16			7
Global revenue
Total Devices	$	735.7		$	676.2		9	%		6	%
Total Masks and other		524.8			454.4		15			12
Total Sleep and Breathing Health	$	1,260.5		$	1,130.6		11			8
Residential Care Software		170.9			161.2		6			4
Total	$	1,431.4		$	1,291.7		11			8

	Nine Months Ended
	March 31, 2026		(A)	March 31, 2025		(A)	% Change			Constant Currency (B)
U.S., Canada, and Latin America
Devices	$	1,309.0		$	1,221.6		7	%
Masks and other		1,119.5			983.9		14
Total U.S., Canada and Latin America	$	2,428.5		$	2,205.6		10
Combined Europe, Asia, and other markets
Devices	$	833.3		$	749.6		11	%		6	%
Masks and other		424.2			368.7		15			7
Total Combined Europe, Asia and other markets	$	1,257.4		$	1,118.3		12			6
Global revenue
Total Devices	$	2,142.3		$	1,971.3		9	%		7	%
Total Masks and other		1,543.6			1,352.6		14			12
Total Sleep and Breathing Health	$	3,685.9		$	3,323.9		11			9
Residential Care Software		503.9			474.4		6			4
Total	$	4,189.8		$	3,798.3		10			8

(A)	Totals and subtotals may not add due to rounding.
(B)	In order to provide a framework for assessing how our underlying businesses performed excluding the effect of foreign currency fluctuations, we provide certain financial information on a “constant currency basis,” which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

Source: Resmed, Inc.

Released April 30, 2026

Source: Government of Western Australia

Local neighbourhoods will soon be greener, with our popular Wannagrow plant giveaway returning this May.

Source: Northern Territory Police and Fire Services

The Northern Territory Police Force can confirm a body has been located as part of the investigation into a missing 5-year-old girl.

The body is believed to be that of the young girl, and was found by police officers around 5km south of Old Timers Camp shortly before midday.

A formal autopsy will be scheduled to confirm the cause of death.

A coronial investigation will now begin.

The family have requested she now be referred to as Kumanjayi Little Baby.

The Northern Territory Police Force Commissioner Martin Dole said, “This is devastating news not only for the immediate and extended family, but also the first responders, the Alice Springs community, and all those around Australia who have been worrying for this little girl.

“The support shown during this time has been overwhelming and this is the worst outcome.

“It is very important the Alice Springs community continues to support one another, and it is equally important that the police continue to do their job.

“Anyone who has any information about the whereabouts of Jefferson Lewis needs to contact police immediately on 131 444 or 000.”

Anonymous reports can be made through Crime Stoppers on 1800 333 000 or via https://crimestoppersnt.com.au.

The below is a statement from Kumanjayi Little Baby’s Mum:

To Kumanjayi Little Baby,

Me and Ramsiah miss and love you.

I know you are in heaven with the rest of the family with Jesus and the Father, Son and Holy Spirit.

Me and your brother will meet you one day.

We are giving our lives to Jesus.

It is going to be so hard to live the rest of our lives without you.

Ramsiah wants to tell you that when he sees you in heaven, he is going to give you the biggest hug ever.

Love from Mum and Ramsiah.

The family have also thanked all the volunteers who have helped with the search so far, everyone who has come from interstate, police, land councils, and everyone else that has turned up every day to look for Kumanjayi Little Baby. 

The family have requested the attached photo of Kumanjayi Little Baby be used in media reporting.  

Source: Prime Minister of Australia

ANTHONY ALBANESE, PRIME MINISTER: On 14 December last year, our nation was shattered by an act which was evil. An antisemitic terrorist attack shook the nation. The deadliest terrorist attack that has ever occurred on Australian soil, targeting Jewish Australians on the first night of Chanukah at our iconic Bondi Beach. This should have been an occasion where every Australian could celebrate what is a victory of light over darkness. Instead, 15 innocent men, women and children were killed and many were wounded. Five months on from the attack, Australia’s Jewish community is still grieving, still hurting, still craving answers. And that’s why my government set up the Royal Commission on Antisemitism and Social Cohesion, led by the Honourable Virginia Bell. To help us understand what happened that day, to help us stamp out the hatred that drove the attackers and to ensure that nothing like this ever happens again. Today the Government is pleased to receive Commissioner Bell’s Interim Report. And I thank the Commissioner for the extraordinary work that she and her team have done. And I thank also those who participated and made submissions and will continue to do so, given they are still open for a short period ahead. Commissioner Bell has found that our existing legal and regulatory frameworks did not hinder our agencies in preventing or responding to the Bondi attack, and that no urgent changes are required to keep Australians safe. But the Commissioner does make 14 recommendations which go to enhancing our national counter-terrorism arrangements and capabilities. This is as the Government envisaged, that the first task of the Royal Commission, the priority was to look at the security elements of these issues. I can confirm that the National Security Committee has met this morning and we have adopted and will implement all the recommendations of the Interim Report that are relevant to the Commonwealth. A number of the recommendations relate to state and territory jurisdictions, aimed at ensuring a nationally consistent approach to implementation. And we’ll work constructively with state and territory governments on those issues. A small number of recommendations are classified because they could compromise sensitive national security information. But I can assure the Australian public that the Government will do everything necessary to protect the community. In the wake of the Bondi attack, my government took immediate action to bolster the resources of our security agencies, tackle antisemitism, crack down on hate preachers and deliver tougher gun laws. That’s why we brought the Parliament back in January. We weren’t able to get the support across the Parliament of everything we wanted to achieve, but we did make substantial progress. Commissioner Bell’s recommendations complement those changes that we already made. I want to thank Commissioner Bell and her team for their hard work and professionalism in delivering this report. My thanks also to Dennis Richardson for leading the Independent Review of Australia’s Federal Law Enforcement and Intelligence Agencies, which became part of the Royal Commission. And I look forward to receiving Commissioner Bell’s final report this year.

< MICHELLE ROWLAND, ATTORNEY-GENERAL

< TONY BURKE, MINISTER FOR HOME AFFAIRS

< JOURNALIST

< PRIME MINISTER:

< JOURNALIST:

< PRIME MINISTER:

< JOURNALIST

< PRIME MINISTER

< MINISTER BURKE

< JOURNALIST

< PRIME MINISTER

< JOURNALIST

< PRIME MINISTER

< JOURNALIST

< PRIME MINISTER

< JOURNALIST

< PRIME MINISTER

< JOURNALIST

< PRIME MINISTER

< JOURNALIST

< PRIME MINISTER

< JOURNALIST

< PRIME MINISTER

< JOURNALIST

< MINISTER BURKE

< JOURNALIST

< MINISTER BURKE

< PRIME MINISTER

< JOURNALIST

< MINISTER BURKE

< PRIME MINISTER

Source: Prime Minister of Australia

ommissioner the Hon Virginia Bell AC has today delivered the Interim Report of the Royal Commission on Antisemitism and Social Cohesion.

The Government welcomes the Interim Report, accepts all recommendations that relate to the Commonwealth, and is committed to working with the states and territories to adopt a national approach to implementation of all 14 recommendations.

While Commissioner Bell found Australia’s existing legal and regulatory frameworks did not hinder agencies’ ability to prevent or respond to the Bondi attack, and that no urgent or immediate action is required, the recommendations go to enhancing our national counter-terrorism arrangements and capabilities.

The Interim Report contains a small number of classified recommendations which cannot be publicly released because they could compromise sensitive national security information. The Government will respond swiftly to these recommendations and Australians will see practical outcomes through a range of policy, program and funding measures.

The Government established the Royal Commission in the wake of the antisemitic terrorist attack at Bondi to examine antisemitism in Australia and strengthen social cohesion.

The Government thanks Commissioner Bell and her team for their professionalism and dedication in delivering the Interim Report. The Government also thanks Mr Dennis Richardson AC for his contribution in leading the independent review of Australia’s federal law enforcement and intelligence agencies, which became part of the Royal Commission.

Source:

Issue date: Thursday, 30 April 2026

The Joint Standing Committee on Aboriginal and Torres Strait Islander Affairs is starting its interstate public hearings in Sydney this week for its inquiry into racism, hate and violence directed at Aboriginal and Torres Strait Islander people.

The first hearing will be held in Sydney on Friday 1 May 2026 and will bring together a broad range of organisations, researchers, community leaders and advocates to provide evidence to the Committee.

Witnesses scheduled to appear include national Aboriginal and Torres Strait Islander education and academic experts, and veterans’ representatives.

Following recent events at ANZAC day commemorations, the final session of the day will hear evidence from Reverand Dr Ray Minniecon and the RSL NSW Acting President, retired Brigadier Vince Williams. This will focus on the experiences of Aboriginal and Torres Strait Islander veterans.

Committee Chair, Mutthi Mutthi and Wamba Wamba woman Senator Jana Stewart, said “These hearings provide an important opportunity for Aboriginal and Torres Strait Islander people, organisations, researchers and advocates to share their experiences and insights directly with the Committee.”

“Racism, hate and violence have real and lasting impacts. Hearing firsthand evidence is essential to understanding the scale and nature of the problem and identifying meaningful responses.”

The inquiry is examining the prevalence, impacts and drivers of racism, hate and violence, as well as existing responses and opportunities for reform. Evidence gathered during the hearings will inform the Committee’s final report to Parliament.

Further interstate public hearings will continue in other locations as part of the inquiry.

Information on the inquiry, including the terms of reference and how to contribute, is available on the Committee’s website.

Please note the committee and secretariat are unable to provide counselling, advice, or support for individuals. Help is available:

For First Nations people:

• 13YARN: 13 92 76
• Brother to Brother: 1800 435 799
• Yarning SafeNStrong: 1800 959 563

For all people:

• Lifeline: Call 13 11 14
• Beyond Blue: 1300 224 636
• MensLine Australia: 1300 789 978
• Kids Helpline: 1800 551 800
• Headspace: 1800 650 890
• Suicide Call Back Service:1300 659 467
• 1800 Respect: 1800 737 732

Media inquiries

Office of Senator Jana Stewart
Media contact: Hannah Purdy
0438 003 838

Source:

---

Source: Airservices Australia

The Account-to-Account Payments Roundtable has today released a public consultation on the draft vision for the future of account-to-account (A2A) payments in Australia. Submissions close 22 May.

The Roundtable brings together Australian Payments Network (AusPayNet), Australian Payments Plus (AP+), the Reserve Bank of Australia (RBA) and Commonwealth Treasury¹.

The publication of the draft vision report for feedback marks the next step in a broader, multi-step process to shape a shared vision for the future of A2A payments in Australia, and a roadmap of high-level deliverables and milestones to achieve that vision. The intention of this work is to provide certainty to stakeholders on the long-term strategic direction for A2A payments, and anchor the industry’s development of A2A payments products, services and underlying infrastructure.

The draft vision has been developed throughout the Roundtable process following extensive engagement with stakeholders and drawing on last year’s consultation on the future of A2A payments undertaken by AusPayNet and AP+.

The A2A payments system is an essential part of Australia’s economy, supporting millions of transactions each day, including the payment of wages, superannuation, welfare and bills, as well as transfers of money to family and friends. The environment for A2A payments is changing rapidly, driven by advances in technology and automation, and shifting societal preferences.

The draft vision sets out the desired long-term outcomes for Australia’s A2A payments system – that it remains safe, reliable, low cost, easy to use, and inclusive for consumers, businesses and government agencies. It also defines the qualities that the system needs to demonstrate to consistently deliver these outcomes.

The Roundtable is seeking input on how the A2A payments system should continue to develop to remain a trusted national asset that meets the evolving needs of its users.

Feedback on the draft vision will be used to refine and finalise the vision. This vision will inform the development of an industry roadmap involving the prioritisation and sequencing of industry deliverables, consistent with public interest considerations.

Next steps

The full consultation paper can be accessed at the following locations:
Future of the Account-to-Account Payments System
<https://auspaynet.com.au/insights/consultations/A2Avision2026>
<https://www.auspayplus.com.au/stakeholder-engagement/public-consultations>

Submissions to this consultation should be submitted via A2Avisionconsultation@auspaynet.com.au. All submissions received will be shared with all members of the A2A Payments Roundtable, unless otherwise specified by the submission respondent. Alternatively, respondents may choose to provide their submission directly to any member of the A2A Payments Roundtable.

Background

Australian Payments Network (AusPayNet) is the self-regulatory body for the payments industry. It administers the framework for the Bulk Electronic Clearing System – Australia’s system for processing batch account-to-account payments, including payroll and welfare payments.

Australian Payments Plus (AP+) is the provider of Australia’s fast payment system – the New Payments Platform – as well as the BPAY billing service.

Source: Northern Territory Police and Fire Services

The Gangs Taskforce has arrested a 47-year-old male following an aggravated assault in Moil on Tuesday night.

Around 11pm, the offender, who was wearing a Mongols OMCG t-shirt attended the residential address of a 53-year-old male known to him and called for him to come to the locked front gate.

The offender then allegedly assaulted the victim through the gate.

Before leaving, the offender allegedly threatened the victim that he would return with other members of the OMCG to assault him.

Around 1:30pm yesterday, the offender was apprehended driving on McMillans Road, and arrested for the assault.

The male underwent a drug test at the Palmerston Watch House which indicated the presence of methamphetamine in his body.

He has been charged with:

– Aggravated assault

– Drive with prohibited drug in body (methamphetamine)

– Drive a motor vehicle while unlicensed

He was remanded to appear later today.